Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Thymoma and Thymic Carcinoma
Is there a role for surgical debulking, local RT or subsequent line of chemotherapy for a patient with stable malignant thymoma but active myasthenia gravis?
Related Questions
What second line therapy do you use for metastatic thymoma that recurs following CAP?
In light of recent retrospective data from France on EGFR TKIs use with PPIs showing negative outcomes in NSCLC patients would you consider discontinuing PPIs or changing PPIs to H2 inhibitors?
Would you use Razor Genomics RiskReveal molecular testing results to guide making recommendations for surgical adjuvant chemotherapy for Stage IA,IB & II non-squamous NSCLCA ?
What treatment would you recommend for a patient with non-mutated Stage III lung squamous cell carcinoma with relapse following neoadjuvant chemoimmunotherapy, surgery, and during adjuvant immunotherapy?
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
How do you decide between neoadjuvant or perioperative chemoimmunotherapy, as per Checkmate 816 or KEYNOTE-671, for early-stage NSCLC?
What treatment options would you consider for a patient with stage IV NSCLC harboring a KRAS-G12A mutation who has progressed after chemoimmunotherapy and prefers to avoid additional chemotherapy?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
Do you perform EBUS-TBNA for staging in patients with biopsy proven malignant lung nodules with no lymphadenopathy on CT chest and PET scan?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
